Panosyan Francis B
Department of Neurology, University of Rochester Medical Center, Rochester, NY.
J Clin Neuromuscul Dis. 2017 Sep;19(1):38-42. doi: 10.1097/CND.0000000000000163.
This case-control study demonstrates that bilateral ptosis due to ocular sympathetic dysfunction is a characteristic feature of Guillain-Barre syndrome (GBS) and apraclonidine can be helpful in unmasking this clinical feature. Five patients with GBS and 9 healthy controls were assessed for ocular sympathetic dysfunction through application of topical apraclonidine to 1 eye. Changes resulting from reversal of ptosis or miosis due to apraclonidine were compared with the eye on the other side with no apraclonidine using photographs. Ocular sympathetic dysfunction in the form of mild bilateral ptosis was found in all 5 patients with GBS recruited in this study. Consistent with previous reports, healthy subjects had no significant response to apraclonidine. Although there was evidence of concomitant pupillary dysfunction in the form of bilateral Horner syndrome in 2 of the patients with GBS with more severe GBS phenotype, this study did not have the statistical power to reach conclusions regarding pupillary dysfunction and disease severity in GBS.
这项病例对照研究表明,眼部交感神经功能障碍所致的双侧上睑下垂是吉兰-巴雷综合征(GBS)的一个特征性表现,而阿可乐定有助于揭示这一临床特征。通过对5例GBS患者和9名健康对照者的1只眼应用局部阿可乐定,评估眼部交感神经功能障碍。使用照片比较因阿可乐定导致上睑下垂或瞳孔缩小逆转而引起的变化与未使用阿可乐定的另一侧眼睛。在本研究纳入的所有5例GBS患者中均发现了轻度双侧上睑下垂形式的眼部交感神经功能障碍。与之前的报告一致,健康受试者对阿可乐定无明显反应。虽然在2例具有更严重GBS表型的GBS患者中有证据显示存在双侧霍纳综合征形式的瞳孔功能障碍,但本研究没有足够的统计学效力就GBS患者的瞳孔功能障碍和疾病严重程度得出结论。